title: Toxic-inflammatory effects of prostoglandin analogs on the ocular surface.
abstract: OBJECTIVE
  To investigate the toxic-inflammatory effects of prostaglandin analogs on the ocular surface.
  
  
  METHODS
  Twenty-three rats were divided into four groups. Bimatoprost 0.03% (I), latanoprost 0.005% (II), and travoprost 0.004% (III) were applied during 6 months; a control group (IV) received no treatment. Dysplasia and keratinization were evaluated on the ocular surface. In the subepithelial area, the number of lymphocytes and mast cells were counted morphologically, and collagen staining densities were compared subjectively in groups.
  
  
  RESULTS
  The ratio of keratinization was 3/12 and 1/10, in groups I and II. The lymphocyte cell counts were 1.4 ± 0.19, 2.2 ± 0.39, 2.27 ± 0.33, and 1.87 ± 0.35 (p > .05). The mast cell counts were 2.58 ± 0.5, 5.4 ± 1.1, 5.7 ± 0.58, and 3.0 ± 0.59. They were significantly higher in groups II and III than in group I (p < .05). Mean collagen density scores were 1.00 ± 0.85, 2.00 ± 0.00, and 1,73 ± 0.70. Group II and III scores were higher than group I scores (p < .05).
  
  
  CONCLUSIONS
  Latanoprost and travoprost seem to have more toxic-inflammatory effects on the ocular surface than bimatoprost.
authors: Department of Ophthalmology, Inonu University, Faculty of Medicine, Malatya, Turkey. sonerdem2000@yahoo.com
authors: Soner
authors: S
authors: Demirel
authors: Selim
authors: S
authors: Doganay
authors: Iclal
authors: I
authors: Gurses
authors: Mustafa
authors: M
authors: Iraz
mesh_terms: D000577:Amides / Q000008:administration & dosage; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D000069580:Bimatoprost; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives; D003228:Conjunctiva / Q000187:drug effects* / Q000473:pathology; D003229:Conjunctival Diseases / Q000139:chemically induced* / Q000473:pathology; D003315:Cornea / Q000187:drug effects* / Q000473:pathology; D003316:Corneal Diseases / Q000139:chemically induced* / Q000473:pathology; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage; D011465:Prostaglandins, Synthetic / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D000069557:Travoprost
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost